Karo Bio Of Sweden Acquires Serra Pharma
Swedish biopharmaceutical company Karo Bio has acquired Serra Pharmaceuticals of the USA, thereby obtaining a leading role in research on the thyroid hormone receptor, as well as expertise and technology which will aid it in its other programs, Karo Bio said. The purchase is financed with a non-cash issue of 50 million Swedish kroner ($7.3 million).
Scientists working for Serra Pharmaceuticals are the first to have solved the structure of the thyroid hormone receptor, which is one of Karo Bio's prioritized targets for drug development. In this field, it is Karo's aim to develop new and more effective treatments for cardiovascular diseases, such as cardiac arrythmias, and their associated risk factors such as hypercholesterolemia.
Private shareholders in Karo Bio include Stena AB and Scios Inc.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze